
Salvia BioElectronics treated its first US patient in RECLAIM-II, a pivotal randomized, double-blind trial of its MySalvia system for resistant migraine. The system uses two ultra-thin implants placed beneath the skin at the front and back of the head, activated twice daily using a wearable device. The study aims to enroll around 150 patients across more than 20 US sites.